Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Lessons from Ten Years’ the Prevalence of Congenital Rubella Syndrome (CRS) in the Young Population Living in a Developing Country, Tehran; Iran

Author(s): Samileh Noorbakhsh*, Mohammad Vafaee-Shahi, Leila Tahernia, Sarvenaz Ashouri and Aina Riahi

Volume 22, Issue 3, 2022

Published on: 31 January, 2022

Article ID: e131221198861 Pages: 6

DOI: 10.2174/1871526521666211213161712

Price: $65

Abstract

Background: A safe and effective rubella vaccine is available and prescribed in IRAN.

Objective: This is a survey of CRS cases collected based on WHO criteria one decade after the MR vaccination campaign (2003).

Methods: This Multi-stage prospective/cross-sectional study was carried out in three stages in 3 educational hospitals in Tehran (Rasoul Aram, Akbar Abadi, and Firoozabadi), In the first stage of the study between 2011 and 2012 total of 186 infants were evaluated, and in the second stage of the study, total 163 blood samples of infants with suspected INTRA UTERINE INFECTION were compared with a group of healthy matched infants. In the first and second stages, Rubella immunity (IgG&IgM) in cord blood was evaluated by the Eliza method.

Results: Despite MR vaccination in Iran, after one decade"confirmed CRS" and " compatible CRS" was diagnosed in 5 and 31 from 89 CRS suspected cases.

Conclusion: The incidence of "confirmed CRS" in every 100 CRS suspected infants (after campaign) is 5.6 %, and 31 CRS Compatible cases are so important. Without active CRS surveillance, mild infection such as IUGR, hearing loss, heart abnormalities, impaired vision, and mental retardation even in the developed country might be missed. Fetal infection is persistent, which imposes additional costs on the country. Another mass vaccination in women and girls is needed. Also, the anti-rubella IgG testing before pregnancy in women who were not vaccinated; vaccination of women before marriage /pregnancy should be obligatory in order to prevent the CRS.

Keywords: Rubella, congenital rubella syndrome, surveillance, immunization programs, children, intrauterine infection.

Graphical Abstract

[1]
Stamos, J.K.; Rowley, A.H. Timely diagnosis of congenital infections. Pediatr. Clin. North Am., 1994, 41(5), 1017-1033.
[http://dx.doi.org/10.1016/S0031-3955(16)38843-5]
[2]
Chauhan, N.; Sen, M.S.; Jhanda, S.; Grover, S. Psychiatric manifestations of congenital rubella syndrome: a case report and review of literature. J. Pediatr. Neurosci., 2016, 11(2), 137-139.
[http://dx.doi.org/10.4103/1817-1745.187643]
[3]
Babigumira, J.B.; Morgan, I.; Levin, A. Health economics of rubella: a systematic review to assess the value of rubella vaccination. BMC Pub. Health, 2013, 13, 406. Published 2013 Apr 29.
[http://dx.doi.org/10.1186/1471-2458-13-406]
[4]
White, S.J.; Boldt, K.L.; Holditch, S.J.; Poland, G.A.; Jacobson, R.M. Measles, mumps, and rubella. Clin. Obstet. Gynecol., 2012, 55(2), 550-559.
[http://dx.doi.org/10.1097/GRF.0b013e31824df256]
[5]
Vaccine Assessment and Monitoring Team of the Department of Vaccines and Biologicals Ordering code: WHO/V&B/99.22 Printed: December 1999. www.who.int/gpv-documents/ World Health Organization. Vaccines and Biologicals. CH-1211 Geneva 27, Switzerland.
[6]
Hendriks, J.; Blume, S. Measles vaccination before the measles mumps-rubella vaccine. Am. J. Public Health, 2013, 103(8), 1393-1401.
[http://dx.doi.org/10.2105/AJPH.2012.301075]
[7]
Sadighi, J.; Eftekhar, H.; Mohammad, K. Congenital rubella syndrome in Iran. BMC Infect. Dis., 2005, 5, 44.
[http://dx.doi.org/10.1186/1471-2334-5-44]
[8]
Vidigal, P.V.T.; Santos, D.V.V.; Castro, F.S. C outo, J.C.F.; Vitor, R.W.A.; Filho, G.B. Prenatal toxoplasmosis diagnosis from amniotic fluid by PCR. Rev. Soc. Bras. Med. Trop., 2002, 35(1), 1-6.
[9]
Faucette, A.N.; Pawlitz, M.D.; Pei, B.; Yao, F.; Chen, K. Immunization of pregnant women: future of early infant protection. Hum. Vaccin. Immunother., 2015, 11(11), 2549-2555.
[10]
Palmeira, P.; Quinello, C.; Silveira-Lessa, A.L.; Zago, C.A.; Carneiro-Sampaio, M. IgG placental transfer in healthy and pathological pregnancies. J. Immunol. Res., 2012. Available from: https://www.hindawi.com/journals/jir/2012/985646/.
[11]
́Masresha, B.; Shibesh, i M.; Kaiser, R.; Luce, R.; Katsande, R.; Mihigo, R. Congenital rubella syndrome in the african region - data from sentinel surveillance. J. Immunol. Sci, 2018(Suppl.), 146-150.
[12]
Marashi, S.M.; Tabatabaei, H.; Mahmoodi, M.; Nategh, R.; Mokhtari-Azad, T. Prevalence of Rubella and HCMV antibodies among neonates. Iran. J. Virol., 2011, 5(3), 34-39.
[13]
Carmen, L.; Charlton, A.S. Dilemmas and pitfalls in rubella laboratory diagnostics in low prevalence or elimination settings. Curr. Treat. Options Infect. Dis., 2016, 8, 329-342.
[http://dx.doi.org/10.1007/s40506-016-0090-8.]
[14]
Dimech, W.; Grangeot-Keros, L.; Vauloup-Fellous, C. Standardization of assays that detect anti-rubella virus IgG antibodies. Clin. Microbiol. Rev., 2016, 29(1), 163-174.
[http://dx.doi.org/10.1128/CMR.00045-15.]
[15]
Soleimanjahi, H.; Fotouhi, F.; Bamdad, T. Evaluation of antibodies against rubella virus in a mass campaign vaccination in Tehran, Iran. Iran. J. Virol, 2010, 4(3&4), 7-11.
[16]
Almassinokiani, F.; Noorbakhsh, S.; Rezaei, M.; Almasi, A.; Akbari, H.; Asadolla, S.; Rahimzadeh, P.; Saberifard, P. What do we need to eradicate rubella in the Islamic Republic of Iran? East. Mediterr. Health J., 2013, 19(9), 807-811.
[17]
Report of a meeting on preventing congenital rubella syndrome: immunization strategies, surveillance needs. Geneva, 12-14 January 2000. The Department of Vaccines and Biologicals. World Health Organization Department of Vaccines and Biologicals CH- 1211 Geneva 27, Switzerland.

Rights & Permissions Print Cite
Article Metrics
13
1
© 2024 Bentham Science Publishers | Privacy Policy